alcohol dehydrogenase 7 (class IV), mu or sigma polypeptideGenealiases: []
Q-omics provides the consensus-scored ADH7 profile across patient tissues and cancer cell-line models. ADH7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADH7 is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, ADH7 protein abundance shows 10,345 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, STAD, and LSCC as cancer lineages where ADH7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADH7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADH7 survival associations across molecular data types. ADH7 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADH7 RNA expression–survival associations across cancer types. High ADH7 expression shows unfavorable associations in KIRC, CHOL, LGG, KICH and SKCM, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADH7 RNA expression.
This table summarizes ADH7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in STAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ADH7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADH7 shows lower tumor expression in STAD, LUAD, HNSC and KIRC and higher tumor expression in LUSC and KICH. The STAD box plot shows higher ADH7 RNA expression in normal versus tumor tissue (log2 FC = −2.637, t-test p < 0.001).
This table shows molecular features associated with ADH7 in patient tissues and cancer cell lines. In patient samples, ADH7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADH7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
